Protein and Energy Metabolism in Pediatric Crohn's Disease

Indiana University

Status and phase

Completed

Phase 1

Conditions

Protein Metabolism

Energy Metabolism

Crohn's Disease

Treatments

Drug: Stable isotope infusions

Study type

Interventional

Funder types

Other

Industry

NIH

Identifiers

NCT00583232

0506-19

IRB 0506-19

Details and patient eligibility

About

The metabolic response to Crohn's disease, including increased proteolysis and lipolysis and changes in energy expenditure, plays a significant role in the resulting malnutrition from which these patients suffer. Tumor necrosis factor-alpha (TNF-alpha), a pro-inflammatory cytokine, has been found to be elevated in children with ulcerative colitis. TNF-alpha has been incriminated in the mechanism of weight loss in many different chronic diseases, and causes net protein and lipid catabolism. Anti-TNF-alpha antibody (infliximab) has been proven to be an effective therapy for ulcerative colitis.

The purpose of this study is to compare changes in protein and lipid metabolism, as well as resting energy expenditure, before and after therapy with anti-TNF-alpha antibody (infliximab) or corticosteroids in children with recurrent Crohn's disease. Performing this study will better define the changes in nutrition status observed in these children following remission of active Crohn's disease, and potentially lead to changes in medical and nutritional management of these children.

Enrollment

15 patients

Sex

All

Ages

6 to 18 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Male and female children between the ages of six and eighteen years of age with recurrence of active Crohn's disease, determined by their primary pediatric gastroenterologist to require either:
1. Corticosteroid therapy ((1-2 mg/kg/d up to maximum of 60 mg/day) with taper, or
2. Infliximab therapy (5 mg/kg at 0, 2, and 6 weeks, followed by q 8 week therapy)
Crohn's disease of at least 3 months since diagnosis, with gastritis, duodenitis, ileitis, ileocolitis, or colitis, confirmed by endoscopy and biopsy
PCDAI score >20
If receiving concomitant medications, must have been on a stable regimen as follows:
1. Subjects on aminosalicylates and/or immunomodulators should be on a stable dose for at least 2 weeks prior to enrollment.
2. Subjects must be off oral, rectal, and parenteral corticosteroids at least 2 weeks prior to enrollment.
Screening laboratory tests that meet the following criteria (obtained within 4 weeks of enrollment):
1. Hemoglobin >8.0 g/dL
2. White blood cell count >3.5 x 109/L
3. Neutrophils >1.5 x 109/L
4. Platelets >100 x 109/L
5. Aspartate aminotransferase, alanine aminotransferase, and alkaline phosphatase levels within 3 times the upper limit of normal.
For those patients to receive infliximab, PPD skin tests with skin induration <5 mm.
Signed written consent from the parent/legal guardian and assent from the child to be obtained prior to enrollment.

Exclusion criteria

Local manifestations of Crohn's disease, including fistula(s), strictures, abscesses, or other complications for which surgery may be indicated.
Surgery for bowel diversion with placement of stoma within 3 months prior to screening.
Positive stool examination of enteric pathogens including Salmonella and Shigella species, Clostridium difficile, and Giardia lamblia.
Female subjects who are pregnant, nursing, or planning pregnancy.
Concomitant diagnosis or history of congestive heart failure.
Treatment with parenteral nutrition within 4 weeks of enrollment.
Serious infection in the 3 months prior to enrollment.
History of prior or current active or latent tuberculosis.
Immune deficiency syndrome, including documented human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS).
History of systemic lupus erythematosus.
A transplanted organ.
Known malignancy or history of malignancy within 5 years of enrollment.
History of demyelinating disease.
History of substance abuse.
Poor tolerability of venipuncture or lack of venous access during the study period.
A live virus vaccination within 3 months of enrollment.
Prior history of infliximab infusion, or any other therapeutic agent targeted at reducing tumor necrosis factor-a (TNF-a).
Hypersensitivity to any murine proteins or other component of infliximab for those patients to receive infliximab.
Inability to comply with study procedures